Errata
Please note, these errata apply to High-Yield Urology 2023. Please email highyieldurology@gmail.com with any additional errors you identify in the book. Many thanks to those who have brought these errata to our attention.
| 31 |
Avelumab and Atezolizumab mechanisms should be listed as PD-L1, not PD-1 |
| 77 | Tamm-Horsfall proteins are erroneously listed as promoters of stone formation and should be listed as inhibitors of stone formation |
Please note, these errata apply to High-Yield Urology 2022.
| Page | Erratum & Correction |
| 7 | "Pheos in RCC" should be corrected to "Pheos in VHL" |
| 16 | The mechanism of Axitinib is erroneously listed as "mAB" and should be corrected to "TKI" as it is a Tyrosine Kinase Inhibitor |
| 26 | Testing Pearl 6g - urine pH with ammonium challenge is erroneously listed as "> 6.8" and should be corrected to "< 6.8" |
| 27 & 37 | The middle rectal artery arises from the Anterior (not Posterior) Branch of the Internal Iliac |
| 31 |
The following agents are listed in the table but do not currently have a role in Advanced UC management: Ipilimumab, Bevacizumab, Lenvatinib, Axitinib Avelumab and Atezolizumab mechanisms should be listed as PD-L1, not PD-1 |
| 53 | "ANC > 15k" should be corrected to "ANC > 1.5k) |
| 70 | Complete distal RTA can cause hyperchloremic (not hypochloremic) metabolic acidosis |
| 70 | Tamm-Horsfall proteins are erroneously listed as promoters of stone formation and should be listed as inhibitors of stone formation |
| 83 | The diagnosis of IC/BPS is erroneously listed as requiring six "months" of symptoms and should be corrected to six "weeks" |
| 126 | "both patterns" should be corrected to "both partners" |